| Literature DB >> 23203969 |
Jason Castle1, Matthew Butts, Andrew Healey, Kevin Kent, Michael Marino, Steven B Feinstein.
Abstract
The potential clinical value of developing a novel, nonviral, ultrasound-directed gene and drug delivery system is immense. Investigators soon will initiate clinical trials with the goal of treating a wide variety of maladies using noninvasive, ultrasound-based technology. The ongoing, scientific validation associated with promising preclinical success portents a novel range of therapeutics. The clinical utility and eventual clinical successes await vigorous testing. This review highlights the recent successes and challenges within the field of ultrasound-mediated drug delivery.Mesh:
Substances:
Year: 2012 PMID: 23203969 DOI: 10.1152/ajpheart.00265.2012
Source DB: PubMed Journal: Am J Physiol Heart Circ Physiol ISSN: 0363-6135 Impact factor: 4.733